What is Supernus Pharmaceuticals's investing cash flow?

Supernus Pharmaceuticals (SUPN) reported investing cash flow of -$19.22M in Q1 2026.

How has Supernus Pharmaceuticals's investing cash flow changed year-over-year?

Supernus Pharmaceuticals's investing cash flow decreased by 151.5% year-over-year, from $37.32M to -$19.22M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Supernus Pharmaceuticals SUPN Investing Cash Flow

Investing Cash Flow at other companies

AbbVieABBV

-$574M+21.9%

Rapport Therapeutics, Inc.RAPP

$37.94M+80.4%

Axsome TherapeuticsAXSM

-$121K+64.2%

Neurocrine BiosciencesNBIX

-$506.2M-3,665%

Jazz PharmaceuticalsJAZZ

$123.1M+173%

Acadia PharmaceuticalsACAD

$66.28M+153%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's investing cash flow?: Supernus Pharmaceuticals (SUPN) reported investing cash flow of -$19.22M in Q1 2026.
How has Supernus Pharmaceuticals's investing cash flow changed year-over-year?: Supernus Pharmaceuticals's investing cash flow decreased by 151.5% year-over-year, from $37.32M to -$19.22M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.